[go: up one dir, main page]

AR018346A1 - Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid - Google Patents

Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid

Info

Publication number
AR018346A1
AR018346A1 ARP990102199A ARP990102199A AR018346A1 AR 018346 A1 AR018346 A1 AR 018346A1 AR P990102199 A ARP990102199 A AR P990102199A AR P990102199 A ARP990102199 A AR P990102199A AR 018346 A1 AR018346 A1 AR 018346A1
Authority
AR
Argentina
Prior art keywords
peptides
mutant
decancer
codify
plasmid
Prior art date
Application number
ARP990102199A
Other languages
English (en)
Original Assignee
Gemvax As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemvax As filed Critical Gemvax As
Publication of AR018346A1 publication Critical patent/AR018346A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se trata de péptidos de producir inmunidad celular T, que comprende: a) un fragmento de al menos 8 aminoácidos, de una proteína mutante que proviene de unmutante en el marco de lectura en un gel de células cancerígenas y b) tienen al menos un aminoácido de la parte mutante de una secuencia de proteínascodificadas por dicho gen; y c) comprenden de 0 a 10 aminoácidos del extremo carboxilo de la parte normal de la secuencia de proteína que precede al extremoamino de la secuencia mutante y puede extenderse más, hacia el extremo carboxilo de la parte mutante de la proteína, segun se determina por un nuevo codonterminador generado por la mutacion por un cambio en el marco de lectura; d) induce, ya sea en toda su longitud o después del procesamiento realizado por unacélula presentadora de antígenos, respuestas de los linfocitos T.
ARP990102199A 1998-05-08 1999-05-10 Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid AR018346A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NO19982097A NO315238B1 (no) 1998-05-08 1998-05-08 Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy

Publications (1)

Publication Number Publication Date
AR018346A1 true AR018346A1 (es) 2001-11-14

Family

ID=19902021

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102199A AR018346A1 (es) 1998-05-08 1999-05-10 Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid

Country Status (12)

Country Link
US (4) US6759046B1 (es)
EP (2) EP1078000B1 (es)
JP (1) JP4591983B2 (es)
CN (1) CN100355781C (es)
AR (1) AR018346A1 (es)
AU (1) AU755712B2 (es)
CA (1) CA2327549C (es)
ES (1) ES2463825T3 (es)
HU (1) HUP0101432A3 (es)
NO (1) NO315238B1 (es)
PL (1) PL344341A1 (es)
WO (1) WO1999058552A2 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
GB2361701A (en) * 2000-04-28 2001-10-31 Norsk Hydro As DNA polymerase delta mutants
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
CA2471735A1 (en) * 2001-08-29 2003-03-13 Kyogo Itoh Desensitizers
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
WO2003087162A2 (en) 2002-04-18 2003-10-23 Mtm Laboratories Ag Neopeptides and methods useful for detection and treatment of cancer
EP1369126A1 (en) * 2002-04-18 2003-12-10 MTM Laboratories AG Use of coding microsatellite region frameshift mutation-derived peptides for treating cancer
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CA2898163C (en) * 2002-12-16 2016-10-11 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7501486B2 (en) 2004-09-07 2009-03-10 Burnham Institute For Medical Research Peptides that selectively home to heart vasculature and related conjugates and methods
EP1796707B1 (en) * 2004-09-07 2011-12-28 The Burnham Institute Peptides that selectively home to heart vasculature and related conjugates and methods
WO2006044923A2 (en) * 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
AU2007220042A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
PL2476435T3 (pl) 2006-08-11 2018-05-30 Life Sciences Research Partners Vzw Peptydy immunogenne i ich zastosowanie w zaburzeniach immunologicznych
NZ580444A (en) * 2007-03-19 2012-02-24 Globeimmune Inc Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US20080293050A1 (en) * 2007-05-25 2008-11-27 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Gene analysis for determination of a treatment characteristic
EP2252329B1 (en) * 2008-02-14 2015-06-17 Life Sciences Research Partners VZW Elimination of immune responses to viral vectors
CA2715536C (en) 2008-02-14 2018-01-16 Life Sciences Research Partners Vzw Cd4+ t-cells with cytolytic properties
AU2008350785B2 (en) * 2008-02-14 2013-10-03 Katholieke Universiteit Leuven Immunogenic peptides and their use in transplantation
CA2724440C (en) * 2008-02-14 2018-01-09 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
ES2676630T3 (es) 2008-02-14 2018-07-23 Life Sciences Research Partners Vzw Control inmunogénico de tumores y células tumorales
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
GB0821616D0 (en) 2008-11-26 2008-12-31 Lytix Biopharma As Compounds
EP2406399B1 (en) 2009-03-09 2018-02-14 Bioatla, LLC Mirac proteins
WO2012069568A2 (en) 2010-11-25 2012-05-31 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
MX355759B (es) 2011-10-28 2018-04-27 Oncotherapy Science Inc Peptidos topk y vacunas que incluyen los mismos.
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
WO2013150532A1 (en) * 2012-04-04 2013-10-10 Yeda Research And Development Co. Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
US9205140B2 (en) 2012-12-13 2015-12-08 Ruprecht-Karls-Universität MSI-specific frameshift peptides (FSP) for prevention and treatment of cancer
JP5890769B2 (ja) * 2012-12-13 2016-03-22 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
CN113956349B (zh) 2014-11-26 2024-09-06 美国卫生和人力服务部 抗突变的kras的t细胞受体
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
JP2016028025A (ja) * 2015-07-29 2016-02-25 ループレヒト−カルルス・ウニヴェルジテート・ハイデルベルクＲｕｐｒｅｃｈｔ−Ｋａｒｌｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｈｅｉｄｅｌｂｅｒｇ がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
ES2874077T3 (es) 2015-09-25 2021-11-04 Imcyse Sa Métodos y compuestos mejorados para eliminar respuestas inmunitarias a agentes terapéuticos
KR20180100302A (ko) * 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
CN108495649A (zh) 2016-01-08 2018-09-04 瓦西博迪公司 治疗性抗癌新表位疫苗
JP6903680B2 (ja) * 2016-03-15 2021-07-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 膵管腺ガンを有する被験体のリスクを評価するための早期かつ非侵襲的な方法及びこのような疾患の処置方法
CA3018748A1 (en) * 2016-03-31 2017-10-05 Neon Therapeutics, Inc. Neoantigens and methods of their use
CA3019266A1 (en) 2016-04-19 2017-10-26 Imcyse Sa Novel immunogenic cd1d binding peptides
GB201608052D0 (en) * 2016-05-09 2016-06-22 Univ Oslo Hf T-cell receptors which recognise frameshift mutants of TGF-beta RII
US11136368B2 (en) * 2016-08-23 2021-10-05 The Cleveland Clinic Foundation Cancer treatment using CX26 blocking peptides
US11260101B2 (en) 2017-02-28 2022-03-01 Jinan University Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
EP3630130B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
IL321690A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Cancer vaccines for uterine cancer
IL280111B2 (en) 2018-07-26 2025-11-01 Curevac Netherlands B V Arid1a, cdkn2a, kmt2b, kmt2d, tp53 and pten vaccines for cancer
CA3106567A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
IL321689A (en) 2018-07-26 2025-08-01 Curevac Netherlands B V Vaccines against breast cancer
CA3106573A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
CA3141951A1 (en) * 2019-05-29 2020-12-03 Hubro Therapeutics As Peptides of tgb.beta.r2 having frameshift mutations
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN113061165A (zh) * 2020-01-02 2021-07-02 厦门大学 EB病毒BNLF2b基因编码多肽及其检测用途
EP4087389A4 (en) * 2020-01-09 2024-02-21 Arizona Board of Regents on behalf of Arizona State University Antibodies and method of producing antibodies
JP2023529322A (ja) * 2020-05-28 2023-07-10 フブロ セラピューティクス エーエス ペプチドカクテル
WO2024052542A2 (en) 2022-09-09 2024-03-14 Hubro Therapeutics As A peptide cocktail

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5700638A (en) * 1993-08-26 1997-12-23 Washington University Cell death regulator
GB9410922D0 (en) * 1994-06-01 1994-07-20 Townsend Alain R M Vaccines
JPH10510988A (ja) * 1994-12-14 1998-10-27 ザ スクリップス リサーチ インスティテュート 腫瘍−特異的細胞毒性ｔ細胞のインビボ活性化
US5866323A (en) * 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
WO1997012992A2 (en) 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
US5973018A (en) * 1995-10-04 1999-10-26 Owens-Corning Fiberglas Technology, Inc. Process for producing shaped phenolic foams
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
AU4907797A (en) 1996-10-10 1998-05-05 Wistar Institute Of Anatomy And Biology, The Methods and compositions for inducing a protective immune response to cancers
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
NO314086B1 (no) 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides

Also Published As

Publication number Publication date
JP4591983B2 (ja) 2010-12-01
EP2374814A3 (en) 2012-01-11
US6759046B1 (en) 2004-07-06
US20110105721A1 (en) 2011-05-05
CA2327549A1 (en) 1999-11-18
WO1999058552A2 (en) 1999-11-18
WO1999058552A3 (en) 2000-03-02
US7192927B2 (en) 2007-03-20
AU755712B2 (en) 2002-12-19
CN100355781C (zh) 2007-12-19
ES2463825T3 (es) 2014-05-29
CA2327549C (en) 2014-10-07
CN1305495A (zh) 2001-07-25
HK1036997A1 (zh) 2002-01-25
NO315238B1 (no) 2003-08-04
NO982097D0 (no) 1998-05-08
EP1078000B1 (en) 2017-03-29
HUP0101432A3 (en) 2004-01-28
EP2374814B1 (en) 2014-03-19
HUP0101432A2 (hu) 2001-08-28
PL344341A1 (en) 2001-11-05
US8614177B2 (en) 2013-12-24
US20050074849A1 (en) 2005-04-07
JP2002519999A (ja) 2002-07-09
US20070004632A1 (en) 2007-01-04
EP1078000A2 (en) 2001-02-28
US7863244B2 (en) 2011-01-04
NO982097L (no) 1999-11-09
EP2374814A2 (en) 2011-10-12
AU5451699A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
AR018346A1 (es) Peptidos mutantes promotores de la inmunidad celular t, composiciones farmaceuticas y vacunas formuladas con dichos peptidos para el tratamiento decanceres; uso de dichos peptidos, metodo para identificar dichos peptidos y secuencias de adn que codifican dichos peptidos mutantes y vectores y plasmid
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
DK0770088T3 (da) Hidtil ukendt cytokin betegner LERK-5.
AR006188A1 (es) &#34;composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion&#34;.
DE3686304D1 (de) Typenspezifische papillomavirus-dns-sequenzen und peptide.
ATE264911T1 (de) Eine universelle immunmodulatorische cytokin- expressierende zelllinie in wartestelling. entsprechende zusammensetzungen und methoden ihrer herstellung und verwendungen
CY1108083T1 (el) Αντιγονα και συνθεσεις του neisseria meningitidis
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
EP0149548A3 (en) Nucleic acid encoding a t-cell antigen receptor polypeptide
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
GB9409985D0 (en) Vaccine against mycobacterial infections
EP1548107A4 (en) CHROMOPROTEIN AND FLUORO PROTEINS
BR9909918A (pt) Método para a liberação de um hormÈnio de crescimento ou citocina de proteìna, peptìdeo ou polipeptìdeo fisiologicamente ativos a um vertebrado não-humano
DE69836520D1 (de) Clostridium perfringens Impfstoff
DE69233311D1 (de) Weidelgraspollen-allergen
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
DE60025704D1 (de) Das goodpasture-antigen bindende protein
NZ334839A (en) Polynucleotide molecules encoding neospora proteins and uses thereof
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
ES2110996T3 (es) Alergeno de polen de ballico.
DE69734586D1 (de) Retinoid-metabolisierendes protein
NO991554D0 (no) Humant vekstgen og kortvekstgenregion
NZ241112A (en) Porcine ryanodine receptor (ryr1), gene, antibodies and method for detecting malignant hyperthermia in pigs